AI has the potential to revolutionize the diagnosis of cancer (Cancer Research Institute, National Institutes of Health). An announced approval of a tool produced in collaboration with another organization will count. The announcement must explicitly characterize the tool as being an AI or machine learning tool. Oncology is the branch of medicine specializing in the diagnosis and treatment of cancer (Cancer.gov - Oncology). Any type of approval that allows the company's tool to be utilized on actual patients outside of a clinical trial will count, including fast-track and emergency authorizations. In the event that two or more companies simultaneously (i.e., exact same date and time) announce a qualifying approval, the answer option listed first (top to bottom) will be considered to have announced first. An already-approved tool of a firm acquired by a major medical diagnostics company will not count.

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.

NOTE 13 August 2025: If a major medical diagnostics company announced regulatory approval from any national or supranational public regulatory body for a novel, AI-driven diagnostic tool prior to 2 June 2025, any announcement of a subsequent approval of the same tool by another public regulatory body will not count.

The question closed "None of the above" with a closing date of 2 October 2025.

See our FAQ to learn about how we resolve questions and how scores are calculated.